Financial Gravity Asset Management, Inc. Intra Cellular Therapies, Inc. Transaction History

Financial Gravity Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jun 26, 2024	BUY	$64.37 - $75.65 $64 - $75	1 New	1 $93,000
Q1 2024 May 13, 2024	BUY	$64.37 - $75.65 $193 - $226	3 New	3 $204,000
Q4 2023 Jun 26, 2024	SELL	$46.37 - $73.65 $139 - $220	-3 Closed	0 $52,000
Q4 2023 Feb 15, 2024	BUY	$46.37 - $73.65 $0 - $0	0 New	0 $0
Q3 2023 Nov 15, 2023	SELL	$52.09 - $64.1 $3,281 - $4,038	-63 Closed	0 $0
Q2 2023 Aug 08, 2023	BUY	$54.67 - $66.44 $3,444 - $4,185	63 New	63 $91,000
Q4 2022 Feb 15, 2023	BUY	$44.07 - $54.45 $2,335 - $2,885	53 New	53 $67,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.